Make your own free website on Tripod.com


Monoclonal Antibiotics




Home
Design
Function
History
Timeline
Problems
Future
Glossary
Bibliography

The Future for Monoclonal Antibodies

Monoclonal antibodies have an advantage over any other drug on the market because they can bind to a certain antigen without affecting anything else. Now the main issue with monoclonal antibodies today is that they are produced in mice and when put in therapeutic use the patient's immune system sees it as being foreign. For the future these monoclonal antibodies need to be manufactured within the human body itself so for therapeutic use the immune system sees it as being normal. Although there are already many monoclonal antibody projects being developed. More than half of these projects are based on CDR-graphed antibodies that are soon to be in the transition from laboratory to clinic. On a whole, monoclonal antibodies amount to a quarter of all biotech products in clinical development. Just over two thirds of these monoclonal antibody projects are working towards:
· Transplant Rejections: bone marrow, kidney.
· Cancer: leukemia, breast cancer.
· Autoimmune diseases: multiple sclerosis.
· Infectious disease: cytomegalovirus.
Monoclonal Antibodies will always offer an advantage in the future because they can practically be programmed to go out bind to specific antigens. There is good evidence to suggest that in the future monoclonal antibodies could take over as the main treatment for the conditions listed above.

Below are some monoclonal antibodies that have already been introduced to modern medicine. These have been directly quoted from another source.

· Omalizumab (Xolair®). Binds to IgE thus preventing IgE from binding to mast cells. Shows promise against allergic asthma.

· Bexxar® (tositumomab). This is a conjugate of a monoclonal antibody against CD20 and the radioactive isotope iodine-131 (131I). It, too, is designed as a treatment for lymphoma. Although both Bexxar® and Zevalin® kill normal B cells, they don't harm the B-cell precursors because these do not express CD20. So, in time, the precursors can repopulate the body with healthy B cells.

· LymphoCide. Binds to CD22, a molecule found on some B-cell leukemia.

· Abciximab (ReoPro®). Inhibits the clumping of platelets by binding the receptors on their surface that normally are linked by fibrinogen. Helpful in preventing reclogging of the coronary arteries in patients who have undergone angioplasty.

iam-2f5.jpg